무작위화 및 임상시험 공급 관리 시장 규모, 점유율, 동향 분석 리포트 : 제공 형태별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Randomization & Trial Supply Management Market Summary

The global randomization and trial supply management (RTSM) market size was estimated at USD 791.6 million in 2025 and is projected to reach USD 2083.8 million by 2033, growing at a CAGR of 13.0% from 2026 to 2033. The growth is driven by the increasing complexity of clinical trials, particularly in areas such as oncology, rare diseases, and advanced therapies.

Modern clinical studies involve adaptive designs, multiple treatment arms, and global multi-site execution, which significantly increases the need for efficient patient randomization and drug supply coordination. randomization and trial supply management (RTSM) platforms address these challenges by enabling real-time management and automation. For instance, in 2025, innovations, such as IQVIA's advanced IRT solutions for early-phase trials, offer flexible configurations and real-time cohort adjustments to handle complex study protocols.

Moreover, the rising adoption of decentralized and hybrid clinical trials (DCTs) is accelerating the demand for RTSM solutions. As clinical trials are shifting toward remote participation, direct-to-patient drug delivery, and virtual monitoring, there is a growing need for systems that can manage distributed inventories and ensure seamless coordination across geographies. RTSM platforms play a critical role in enabling these capabilities, supporting patient-centric trial models and improving accessibility, which in turn drives their widespread adoption.

The growing emphasis on regulatory compliance and data integrity is further reinforced by evolving global guidelines and increasing inspection scrutiny. For instance, updated ICH E6(R3) guidelines now position RTSM/IRT systems as quality-critical infrastructure, requiring robust audit trails, real-time traceability, and risk-based oversight across the clinical trial lifecycle. Regulators increasingly expect systems to clearly document "who, when, and why," ensuring full transparency and inspection readiness. In addition, in July 2025, IQVIA highlighted a rise in regulatory inspections involving RTSM systems since 2021, continuing into 2025, with a greater focus on data integrity, audit trails, and system validation. This trend is pushing sponsors and CROs to adopt advanced RTSM platforms that provide automated tracking, secure data management, and compliance-ready reporting, thereby accelerating market growth.

Furthermore, the ongoing digital transformation of clinical trial operations, including the integration of AI and cloud-based technologies, is significantly enhancing the capabilities of RTSM platforms. Advanced systems now incorporate predictive analytics for supply optimization and risk management, improving trial efficiency and reducing costs. For instance, in June 2025, Oracle introduced interoperability enhancements in its RTSM solution, enabling drug pooling and automated supply management across multiple trials and vendors, thereby improving efficiency and accelerating clinical trial timelines.

Global Randomization And Trial Supply Management Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global randomization and trial supply management (RTSM) market report based on delivery mode, end-use, and region:

• Delivery Mode Outlook (Revenue, USD Million, 2021 - 2033)
• On-premise
• Cloud and web-based
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• CROs
• Academic Institutes
• Pharma & Biotech Organizations
• Medical Device Manufacturers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • New Zealand
  • Taiwan
  • Hong Kong
  • Singapore
  • Vietnam
• Latin America
  • Brazil
  • Argentina
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Qatar
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Delivery Mode
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2
  • 1.9.3. Objective 3

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Delivery Mode Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Randomization and Trial Supply Management (RTSM) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Industry Value Chain Analysis
  • 3.2.1. Reimbursement framework
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Increasing complexity of clinical trials
    • 3.3.1.2. Rising adoption of decentralized and hybrid clinical trials (DCTs)
    • 3.3.1.3. Growing demand for regulatory compliance and data integrity
    • 3.3.1.4. Digital transformation and adoption of cloud-based eClinical solutions
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. High implementation and operational costs
    • 3.3.2.2. Integration challenges with legacy clinical trial systems
  • 3.3.3. Market Opportunity Analysis
  • 3.3.4. Industry Challenge
• 3.4. Randomization and Trial Supply Management (RTSM) Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Social landscape
    • 3.4.2.4. Economic landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Randomization and Trial Supply Management (RTSM) Market: Delivery Mode Estimates & Trend Analysis

• 4.1. Delivery Mode Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Randomization and Trial Supply Management (RTSM) Market by Delivery Mode Outlook
  • 4.3.1. Cloud and web-based
    • 4.3.1.1. Cloud and web-based market estimates and forecast 2021 to 2033 (USD Million)
  • 4.3.2. On-premise
    • 4.3.2.1. On-premise market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Randomization and Trial Supply Management (RTSM) Market: End Use Estimates & Trend Analysis

• 5.1. End use Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Randomization and Trial Supply Management (RTSM) Market by End Use Outlook
  • 5.3.1. Hospitals
    • 5.3.1.1. Hospitals market estimates and forecast 2021 to 2033 (USD Million)
  • 5.3.2. CROs
    • 5.3.2.1. CROs market estimates and forecast 2021 to 2033 (USD Million)
  • 5.3.3. Academic Institutes
    • 5.3.3.1. Academic institutes market estimates and forecast 2021 to 2033 (USD Million)
  • 5.3.4. Pharma & Biotech Organizations
    • 5.3.4.1. Pharma & biotech organizations market estimates and forecast 2021 to 2033 (USD Million)
  • 5.3.5. Medical Device Manufacturers
    • 5.3.5.1. Medical device manufacturers market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Randomization and Trial Supply Management (RTSM) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Regional Market Snapshot
• 6.4. Market Size, Forecasts, & Trends Analysis, 2021 to 2033:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.6. Sweden
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.7. Netherlands
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.6.9. Norway
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.4. South Korea
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.5. Thailand
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.6. Australia
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.7. New Zealand
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.8. Taiwan
    • 6.7.8.1. Key country dynamics
    • 6.7.8.2. Regulatory framework
    • 6.7.8.3. Competitive scenario
    • 6.7.8.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.9. Hong Kong
    • 6.7.9.1. Key country dynamics
    • 6.7.9.2. Regulatory framework
    • 6.7.9.3. Competitive scenario
    • 6.7.9.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.10. Singapore
    • 6.7.10.1. Key country dynamics
    • 6.7.10.2. Regulatory framework
    • 6.7.10.3. Competitive scenario
    • 6.7.10.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.7.11. Vietnam
    • 6.7.11.1. Key country dynamics
    • 6.7.11.2. Regulatory framework
    • 6.7.11.3. Competitive scenario
    • 6.7.11.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.8.3. Chile
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.9.4. Qatar
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.9.5. Egypt
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.9.6. Kuwait
    • 6.9.6.1. Key country dynamics
    • 6.9.6.2. Regulatory framework
    • 6.9.6.3. Competitive scenario
    • 6.9.6.4. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key Company Market Share Analysis, 2025 (%)
• 7.4. Key Company Market Position Analysis, 2025
• 7.5. Company Profiles
  • 7.5.1. IQVIA
    • 7.5.1.1. Company overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. Oracle
    • 7.5.2.1. Company overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. Medidata (Acquired by Dassault Systemes)
    • 7.5.3.1. Company overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Veeva Systems Inc.
    • 7.5.4.1. Company overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Parexel
    • 7.5.5.1. Company overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. Suvoda LLC
    • 7.5.6.1. Company overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. 4G Clinical
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Signant Health
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Calyx
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Almac Group
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. Clinion
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Product benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. Mednet
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Product benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. ICON plc
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Product benchmarking
    • 7.5.13.4. Strategic initiatives